558 related articles for article (PubMed ID: 18836691)
41. Susceptibility testing of clinical isolates of pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating pseudomonas ocular infections.
Epstein SP; Bottone EJ; Asbell PA
Eye Contact Lens; 2006 Sep; 32(5):240-4. PubMed ID: 16974157
[TBL] [Abstract][Full Text] [Related]
42. Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis.
Thibodeaux BA; Dajcs JJ; Caballero AR; Marquart ME; Girgis DO; O'Callaghan RJ
Curr Eye Res; 2004 May; 28(5):337-42. PubMed ID: 15287370
[TBL] [Abstract][Full Text] [Related]
43. The effect of fourth-generation fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomy.
Burka JM; Bower KS; Vanroekel RC; Stutzman RD; Kuzmowych CP; Howard RS
Am J Ophthalmol; 2005 Jul; 140(1):83-7. PubMed ID: 15953577
[TBL] [Abstract][Full Text] [Related]
44. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.
Dajcs JJ; Thibodeaux BA; Marquart ME; Girgis DO; Traidej M; O'Callaghan RJ
Antimicrob Agents Chemother; 2004 Jun; 48(6):1948-52. PubMed ID: 15155183
[TBL] [Abstract][Full Text] [Related]
45. Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.
van der Heijden YF; Maruri F; Blackman A; Mitchel E; Bian A; Shintani AK; Eden S; Warkentin JV; Sterling TR
Int J Antimicrob Agents; 2013 Sep; 42(3):232-7. PubMed ID: 23806638
[TBL] [Abstract][Full Text] [Related]
46. Ophthalmic infections and their anti-infective challenges.
Alfonso E; Crider J
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S1-6. PubMed ID: 16257307
[TBL] [Abstract][Full Text] [Related]
47. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients.
Rolston KV; Yadegarynia D; Kontoyiannis DP; Raad II; Ho DH
Int J Infect Dis; 2006 May; 10(3):223-30. PubMed ID: 16439177
[TBL] [Abstract][Full Text] [Related]
48. Comparison of in vitro susceptibilities of ocular bacterial isolates to gatifloxacin and other topical antibiotics.
Kaliamurthy J; Nelson Jesudasan CA; Geraldine P; Parmar P; Kalavathy CM; Thomas PA
Ophthalmic Res; 2005; 37(3):117-22. PubMed ID: 15746568
[TBL] [Abstract][Full Text] [Related]
49. Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae.
Hedlin P; Blondeau JM
Eye Contact Lens; 2007 May; 33(3):161-4. PubMed ID: 17502752
[TBL] [Abstract][Full Text] [Related]
50. In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients.
Rolston KV; Vaziri I; Frisbee-Hume S; Streeter H; LeBlanc B
Chemotherapy; 2004 Nov; 50(5):214-20. PubMed ID: 15523180
[TBL] [Abstract][Full Text] [Related]
51. In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates.
Miller D; Flynn PM; Scott IU; Alfonso EC; Flynn HW
Arch Ophthalmol; 2006 Apr; 124(4):479-83. PubMed ID: 16606872
[TBL] [Abstract][Full Text] [Related]
52. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Moczygemba LR; Frei CR; Burgess DS
Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
[TBL] [Abstract][Full Text] [Related]
53. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans.
Robertson SM; Curtis MA; Schlech BA; Rusinko A; Owen GR; Dembinska O; Liao J; Dahlin DC
Surv Ophthalmol; 2005 Nov; 50 Suppl 1():S32-45. PubMed ID: 16257309
[TBL] [Abstract][Full Text] [Related]
54. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms.
Almer LS; Hoffrage JB; Keller EL; Flamm RK; Shortridge VD
Antimicrob Agents Chemother; 2004 Jul; 48(7):2771-7. PubMed ID: 15215148
[TBL] [Abstract][Full Text] [Related]
55. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.
Saravolatz LD; Leggett J
Clin Infect Dis; 2003 Nov; 37(9):1210-5. PubMed ID: 14557966
[TBL] [Abstract][Full Text] [Related]
56. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
[TBL] [Abstract][Full Text] [Related]
57. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Bauernfeind A
J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
[TBL] [Abstract][Full Text] [Related]
58. Immunomodulatory effect of gatifloxacin on mouse peritoneal macrophages in vitro and in models of endotoxin-induced rat conjunctivitis and rabbit bacterial keratitis.
Wada T; Kida T; Inoue T; Tokushige H; Naka H; Sakaki H
Ophthalmic Res; 2008; 40(2):54-60. PubMed ID: 18223298
[TBL] [Abstract][Full Text] [Related]
59. In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections.
Ozdek SC; Miller D; Flynn PM; Flynn HW
Ocul Immunol Inflamm; 2006 Dec; 14(6):347-51. PubMed ID: 17162605
[TBL] [Abstract][Full Text] [Related]
60. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
